Spots Global Cancer Trial Database for acral lentiginous melanoma
Every month we try and update this database with for acral lentiginous melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | NCT04511013 | Acral Lentigino... Clinical Stage ... Metastatic Cuta... Metastatic Mali... Metastatic Mela... Metastatic Muco... Pathologic Stag... | Binimetinib Encorafenib Ipilimumab Nivolumab | 18 Years - | SWOG Cancer Research Network | |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | NCT03025256 | Acral Lentigino... Central Nervous... Clinical Stage ... Leptomeningeal ... Melanocytoma Metastatic Lung... Metastatic Mela... Metastatic Muco... Metastatic Uvea... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Lumbar Puncture Magnetic Resona... Nivolumab Positron Emissi... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | NCT04244552 | Breast Cancer Colorectal Canc... Ovarian Cancer Non-Small Cell ... Acral Lentigino... Head and Neck S... Hepatocellular ... Esophageal Squa... Urothelial Carc... DMMR Colorectal... MSI-H Colorecta... Melanoma Platinum-Resist... Platinum-Resist... Platinum-Resist... Triple Negative... | ATRC-101 Pembrolizumab Pegylated lipos... | 18 Years - | Atreca, Inc. | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| Dinaciclib in Treating Patients With Stage IV Melanoma | NCT00937937 | Acral Lentigino... Cutaneous Nodul... Lentigo Maligna... Low-CSD Melanom... Mucosal Melanom... Recurrent Melan... Stage IV Cutane... | Dinaciclib | 18 Years - | National Cancer Institute (NCI) | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | NCT01092728 | Melanoma | Dasatinib Surgical Resect... | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma | NCT02875132 | Acral Lentigino... | pembrolizumab | 18 Years - | Chinese University of Hong Kong | |
| Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | NCT01092728 | Melanoma | Dasatinib Surgical Resect... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | NCT03698019 | Acral Lentigino... Clinical Stage ... Clinical Stage ... Mucosal Melanom... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
